University Hospital Brno - FN Brno
Brno, Czech Republic, 62500, Czechia
NCT Number: NCT02546843
This randomized study prospectively evaluates our experience with administration of cisatracurium and rocuronium antagonized by sugammadex and evaluates the effects of various depths of neuromuscular blockage on providing optimal surgical conditions during laparoscopy with low-pressure capnoperitoneum.
Looking for future studies?
Notify Me2 year–18 year
All sexes
Interventional
Not applicable
Brno, Czech Republic, 62500, Czechia
This randomized study prospectively evaluates our experience with administration of cisatracurium and rocuronium antagonized by sugammadex and evaluates the effects of various depths of neuromuscular blockage on providing optimal surgical conditions during laparoscopy with low-pressure capnoperitoneum.
After meeting inclusion criteria the patients will be randomized - - use of opaque envelopes, randomization into groups A and B in an operating theatre, study blinded for the patient (or his/her legal guardian) and surgeon.
Group A - muscle relaxation using rocuronium followed by sugammadex reversal (in a dose according to TOF - (train-of-four) 2-4mg/kg), depth of muscle relaxation TOF 0 PTC (post-tetanic count) 0-1 Group B - muscle relaxation using cisatracurium followed by decurarization (neostigmine 0.03 mg/kg and atropine 0.02 mg/kg)
Anesthesia management:
Management of neuromuscular blockade:
Group A - maintaining of deep muscular blockage - according to TOF 0, PTC 0-1, boluses of rocuronium 0.3 mg/kg are allowed Group B - maintaining of muscular relaxation TOF 1, boluses of cisatracurium 0.03 mg/kg are allowed Laparoscopy - capnoperitoneum pressure - 10 mmHg with a reduction to 8 mmHg if possible
During the surgery the surgical conditions will be scored by using Surgical scoring system: (1-2 surgeons involved):
Recovery from anesthesia:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
Other names: Esmeron
cisatracurium 0.15mg/kg intravenously
Other names: Nimbex
neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
Other names: neuromuscular blockade
repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
Other names: neuromuscular blockade
Time frame: intraoperatively
During the surgery the blinded surgeon will grade surgical conditions due to surgical scoring system
Time frame: intraoperatively
The adverse events will be monitored
Brno University Hospital
Other
Deep Neuromuscular Blockade During Laparoscopic Surgery in Pediatric Patient and the Impact of the Depth of the Blockade on the Surgery Conditions, Perioperative Complications and Surgeon Satisfaction
Acronym: PedLapBlock
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06220136
Anesthesia, General, Neuromuscular Blockade
Ankara, Altındağ, Turkey (Türkiye)
View Trial DetailsNCT07580144
Atrophy, Frailty
Konya, Turkey (Türkiye)
View Trial DetailsNCT05006807
Neuromuscular Blockade
Seattle, Washington, United States
View Trial DetailsNCT07404579
Neuromuscular Blockade
Zhengzhou, Henan, China
View Trial Details